Amneal Pharmaceuticals, Inc.
Income Statement
| Line Item | FY2017 | FY2016 |
|---|---|---|
| Revenue | $1.03B | $1.02B |
| Cost of Revenue | $507.5M | $420.8M |
| Gross Profit | $526.2M | $597.5M |
| Gross Margin | 50.9% | 58.7% |
| Operating Expenses | ||
| Research & Development | $171.4M | $179.0M |
| SG&A Expense | $109.0M | $118.8M |
| Operating Income | $245.1M | $284.9M |
| Operating Margin | 23.7% | 28.0% |
| Interest Expense | — | — |
| Pretax Income | $171.3M | $214.8M |
| Income Tax Expense | $2.0M | $5.4M |
| Net Income | $0 | $0 |
| Net Margin | 0.0% | 0.0% |
| EPS (Basic) | — | — |
| EPS (Diluted) | — | — |
| Shares Outstanding (Basic) | 1.0K | — |
| Shares Outstanding (Diluted) | 1.0K | — |
| Dividends Per Share | — | — |